

Bridging the Gap Between Technologies and Viable Companies

Randy H. Weiss, Ph.D. Vice President, Sourcing and Due Diligence BioGenerator


March 30, 2007

Powering ventures into reality

1



Bridging the Gap



Powering ventures into reality



Mission

- Identify life science technologies with sufficient commercial potential such that a start-up company can be formed
- Provide information and advice to faculty/entrepreneurs about the commercialization process and how to start a company
- Provide funding and management support to initiate company operations and to achieve key company milestones
- Assist start-up in attracting side-by-side and/or follow-on funding (e.g. VCs, angels, SBIR/STTR grants, corporate partners)



Organization

- Not-for-profit corporation; operations began 10/03
- \$6 million funding from:
 - The Danforth Foundation
 - James S. M^cDonnell Foundation
 - The Monsanto Fund
 - Bunge, North America, Inc.
- Office located at the Nidus Center incubator on Monsanto's campus in Creve Coeur
- Work closely with university technology transfer offices




Seed Fund Investments

- Technologies: Plant & Life Sciences (broadly defined)
- Geographic Scope: St. Louis Region
- Stage of Company: Start-up or Emerging Technology
- Typical Investment
 - \$50K \$500K cash; up to 24 month funding period
 - Deal structure
 - Equity (common shares with minority shareholder rights)
 - Convertible debt (converts to preferred shares at Series A funding
 - Side-by-side investment as needed (e.g. angels, VCs)



Major Functions



Powering ventures into reality







Powering ventures into reality



Investor Advisory Board

Objective

 Identify milestones that need to be achieved and critical issues that need to be addressed by company to make it a viable candidate for Series A funding

Members

- Prolog Ventures (St. Louis)
- RiverVest Venture Partners (St. Louis)
- Triathlon Medical Ventures (OH)
- CID Equity (IN)
- Charter Life Science Ventures (CA)
- Mason Wells BioMedical Fund (WI)
- Arch Development Partners (IL)
- Arboretum Ventures (MI)
- RCT Ventures (AZ)
- HIG Ventures (FL)
- Arch Angels (St. Louis)



Operations Committee

- Objective
 - Approve funding for proposed investments
- Members
 - Bob Calcaterra, D.Sc. (Nidus Center for Scientific Enterprise)
 - Marcia Mellitz (Center for Emerging Technologies)
 - Brad Castanho, Ph.D./Mike Marrah (Washington University)
 - Joe Zahner, Ph.D. (Saint Louis University)



Investments - Graduates

Akermin, Inc.



Nick Akers & Shelley Minteer

• Biofuel cells (Saint Louis University)

- Founders: Nick Akers and Shelley Minteer, Ph.D.
- BioGenerator \$400,000; Saint Louis University \$250,000
- Status: Graduated(12/05); Raised \$3 Million VC and Angel round



Monique Spann-Wade

ISW Group, Inc.

- Dermatological products (Independent)
- Founders: Monique Spann-Wade and Essien Ita
- BioGenerator \$400,000; angels \$500,000
- Status: Graduated (07/06); \$2.1 million DOD award; clinical trials underway



Investments - Current



Chuck Niblett & Ana Bailey

Venganza, Inc.

- Gene silencing of fungal pathogens (Independent)
- Founders: Chuck Niblett, Ph.D. and Ana Bailey, Ph.D.
- BioGenerator \$500,000; Co-Founders \$100,000
- Status: Corporate partner negotiations underway



Ridong Chen

APT Therapeutics, Inc.

- Anti-platelet therapy for the treatment of acute thrombosis (Independent)
- Founders: Ridong Chen, Ph.D
- Side-by-side investment with Prolog Ventures
- Status: Awarded \$790K Phase II SBIR grant



Investments - Current



Tom Baranski



Ross Cagan

Medros, Inc.

- Medros = Medicines from *Drosophila* (fruit flies)
- Pharmaceuticals for cancer and diabetes (Washington Univ.)
- Founders: Tom Baranski, M.D. and Ross Cagan, Ph.D.
- BioGenerator \$500,000 (convertible debt)
- Status: Closed July 2006; awarded Phase I STTR grant



Biomedical Engineering Deals

- Igor Efimov, Ph.D., Washington University -Medical devices to deliver painless therapy for ventricular and atrial fibrillation
- Eric Leuthardt, M.D. and Dan Moran, Ph.D., Washington University - Communication devices using brain-computer interface technology, e.g. for epilepsy patients